- Home
- IMNM vs BBNX Comparison
IMNM vs BBNX Comparison
Compare IMNM & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- BBNX
- Stock Information
- Founded
- IMNM 2006
- BBNX 2015
- Country
- IMNM United States
- BBNX United States
- Employees
- IMNM N/A
- BBNX N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- BBNX Medical/Dental Instruments
- Sector
- IMNM Health Care
- BBNX Health Care
- Exchange
- IMNM Nasdaq
- BBNX Nasdaq
- Market Cap
- IMNM 748.3M
- BBNX 841.5M
- IPO Year
- IMNM 2020
- BBNX 2025
- Fundamental
- Price
- IMNM $8.75
- BBNX $17.89
- Analyst Decision
- IMNM Strong Buy
- BBNX Strong Buy
- Analyst Count
- IMNM 5
- BBNX 10
- Target Price
- IMNM $26.40
- BBNX $25.20
- AVG Volume (30 Days)
- IMNM 874.4K
- BBNX 519.2K
- Earning Date
- IMNM 08-11-2025
- BBNX 08-06-2025
- Dividend Yield
- IMNM N/A
- BBNX N/A
- EPS Growth
- IMNM N/A
- BBNX N/A
- EPS
- IMNM N/A
- BBNX N/A
- Revenue
- IMNM $10,938,000.00
- BBNX $69,830,000.00
- Revenue This Year
- IMNM N/A
- BBNX $32.79
- Revenue Next Year
- IMNM $349.38
- BBNX $36.59
- P/E Ratio
- IMNM N/A
- BBNX N/A
- Revenue Growth
- IMNM N/A
- BBNX 38911.17
- 52 Week Low
- IMNM $5.15
- BBNX $8.89
- 52 Week High
- IMNM $16.81
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- IMNM 48.43
- BBNX N/A
- Support Level
- IMNM $9.02
- BBNX N/A
- Resistance Level
- IMNM $9.91
- BBNX N/A
- Average True Range (ATR)
- IMNM 0.55
- BBNX 0.00
- MACD
- IMNM -0.08
- BBNX 0.00
- Stochastic Oscillator
- IMNM 9.37
- BBNX 0.00
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.